Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 171

Similar articles for PubMed (Select 23723255)

1.

The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.

Johansson M, Oudin A, Tiemann K, Bernard A, Golebiewska A, Keunen O, Fack F, Stieber D, Wang B, Hedman H, Niclou SP.

Neuro Oncol. 2013 Sep;15(9):1200-11. doi: 10.1093/neuonc/not054. Epub 2013 May 30.

2.

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.

Mol Cancer Ther. 2009 Jul;8(7):1751-60. doi: 10.1158/1535-7163.MCT-09-0188. Epub 2009 Jul 7.

3.

Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.

Xiao Q, Tan Y, Guo Y, Yang H, Mao F, Xie R, Wang B, Lei T, Guo D.

PLoS One. 2014 Oct 29;9(10):e111419. doi: 10.1371/journal.pone.0111419. eCollection 2014.

4.

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.

Longo SL, Padalino DJ, McGillis S, Petersen K, Schirok H, Politz O, Canute GW, Post DE.

Invest New Drugs. 2012 Dec;30(6):2161-72. doi: 10.1007/s10637-011-9784-4. Epub 2011 Dec 29.

PMID:
22203214
5.

Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.

Ye F, Gao Q, Xu T, Zeng L, Ou Y, Mao F, Wang H, He Y, Wang B, Yang Z, Guo D, Lei T.

J Neurooncol. 2009 Sep;94(2):183-94. doi: 10.1007/s11060-009-9836-1. Epub 2009 Mar 20.

PMID:
19300910
6.

The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.

Estrada-Bernal A, Lawler SE, Nowicki MO, Ray Chaudhury A, Van Brocklyn JR.

J Neurooncol. 2011 May;102(3):353-66. doi: 10.1007/s11060-010-0345-z. Epub 2010 Oct 12.

7.

Direct inhibition of retinoblastoma phosphorylation by nimbolide causes cell-cycle arrest and suppresses glioblastoma growth.

Karkare S, Chhipa RR, Anderson J, Liu X, Henry H, Gasilina A, Nassar N, Roychoudhury J, Clark JP, Kumar A, Pauletti GM, Ghosh PK, Dasgupta B.

Clin Cancer Res. 2014 Jan 1;20(1):199-212. doi: 10.1158/1078-0432.CCR-13-0762. Epub 2013 Oct 29.

8.

Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.

Wang H, Shi B, Zhang Q, Jiang H, Hu S, Kong J, Yao M, Yang S, Li Z.

FASEB J. 2012 Jan;26(1):73-80. doi: 10.1096/fj.11-191064. Epub 2011 Sep 14.

9.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

10.

High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor.

Auf G, Jabouille A, Delugin M, Guérit S, Pineau R, North S, Platonova N, Maitre M, Favereaux A, Vajkoczy P, Seno M, Bikfalvi A, Minchenko D, Minchenko O, Moenner M.

BMC Cancer. 2013 Dec 13;13:597. doi: 10.1186/1471-2407-13-597.

11.

EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.

Geoerger B, Gaspar N, Opolon P, Morizet J, Devanz P, Lecluse Y, Valent A, Lacroix L, Grill J, Vassal G.

Int J Cancer. 2008 Jul 1;123(1):209-16. doi: 10.1002/ijc.23488.

PMID:
18386816
12.

Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.

Li B, Chang CM, Yuan M, McKenna WG, Shu HK.

Cancer Res. 2003 Nov 1;63(21):7443-50.

13.

Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.

Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK.

Clin Cancer Res. 2004 Oct 1;10(19):6732-43.

14.

Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.

Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.

Cancer Res. 2006 Jan 15;66(2):867-74.

15.

Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.

Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15984-9. doi: 10.1073/pnas.1113416108. Epub 2011 Sep 6.

16.

Blockade of glioma proliferation through allosteric inhibition of JAK2.

He K, Qi Q, Chan CB, Xiao G, Liu X, Tucker-Burden C, Wang L, Mao H, Lu X, McDonald FE, Luo H, Fan QW, Weiss WA, Sun SY, Brat DJ, Ye K.

Sci Signal. 2013 Jul 9;6(283):ra55. doi: 10.1126/scisignal.2003900.

PMID:
23838182
17.

The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.

Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG.

Neoplasia. 2009 May;11(5):448-58, 2 p following 458.

19.

LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.

Qi XC, Xie DJ, Yan QF, Wang YR, Zhu YX, Qian C, Yang SX.

Biochem Biophys Res Commun. 2013 Aug 9;437(4):565-72. doi: 10.1016/j.bbrc.2013.06.116. Epub 2013 Jul 9.

PMID:
23850692
20.

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG.

Clin Cancer Res. 2005 Sep 1;11(17):6390-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk